CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 11 enrolled
Drug / intervention
Wilatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03376516
NCT03376516Phase 3Completed
CompareCT.gov

Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A

Octapharma·interventional·Posted Dec 18, 2017·Updated Jan 19, 2021

In Brief

A Phase 3 clinical trial evaluating Wilate for Severe Hemophilia A. Completed, enrolled 11 participants across 3 sites in 2 countries.

Detailed Summary

A prospective, non-controlled, international, multi-centre phase 3 study to investigate the pharmacokinetics, efficacy, safety, and immunogenicity of Wilate in previously treated children with severe haemophilia A

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSevere Hemophilia A
CountriesRussia, Ukraine
Collaborators--

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedDec 18, 2017
Enrollment StartNov 22, 2017
Primary CompletionNov 3, 2018
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 8.5 years ago

Interventions

Wilatedrug

von Willebrand factor / Factor VIII (plasma derived)